905593-24-0Relevant academic research and scientific papers
Pharmacophore-based small molecule CXCR4 ligands
Narumi, Tetsuo,Tanaka, Tomohiro,Hashimoto, Chie,Nomura, Wataru,Aikawa, Haruo,Sohma, Akira,Itotani, Kyoko,Kawamata, Miyako,Murakami, Tsutomu,Yamamoto, Naoki,Tamamura, Hirokazu
scheme or table, p. 4169 - 4172 (2012/07/03)
Low molecular weight CXCR4 ligands were developed based on the peptide T140, which has previously been identified as a potent CXCR4 antagonist. Some compounds with naphthyl, fluorobenzyl and pyridyl moieties as pharmacophore groups in the molecule showed significant CXCR4-binding activity and anti-HIV activity. Structure-activity relationships were studied and characteristics of each of these three moieties necessary for CXCR4 binding were defined. In this way, CXCR4 ligands with two types of recognition modes for CXCR4 have been found.
Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs
Tamamura, Hirokazu,Tsutsumi, Hiroshi,Masuno, Hiroyuki,Mizokami, Satoko,Hiramatsu, Kenichi,Wang, Zixuan,Trent, John O.,Nakashima, Hideki,Yamamoto, Naoki,Peiper, Stephen C.,Fujii, Nobutaka
, p. 2354 - 2357 (2008/09/18)
A linear type of several low molecular weight CXCR4 antagonists were developed based on T140 analogs, which were previously found to be strong CXCR4 antagonists that block X4-HIV-1 entry and have inhibitory activities against cancer metastasis/progression and rheumatoid arthritis. The Royal Society of Chemistry 2006.
